Ardea Biosciences — Corporate Update (November 2010)
37 slides from Ardea Biosciences's corporate update, Nov 8, 2010
Slide 1: Ardea Biosciences Company Update
Ardea Biosciences Company Update November 8, 2010
Slide 2: Forward-looking statements
Statements contained in this presentation regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially
Slide 3: Development pipeline
Discovery Preclinical Phase 0/1 Phase 2 A B Phase 3 MEKI for cancer 3 Gout RDEA594 Next Generation MEKI + sorafenib for cancer RDEA119 RDEA119 Gout
Slide 4: Hyperuricemia/Gout
HYPERURICEMIA/GOU T 4
Slide 5: Allopurinol does a poor job treating severe disease
5 1. Perez-Ruiz F, Arthritis Rheum 2002;47:356-360 Allopurinol does a very poor job of treating severe disease (Images are courtesy of Nicola Dalbeth) Velocity of Tophi Reduction1
Slide 6: Gout caused by elevated serum uric acid; RDEA594 increases excretion
Gout is caused by abnormally elevated levels of serum uric acid (>6.8 mg/dL) Increasing incidence and severity in US: approximately 8 million patients ~ 90% of patients are "under-excretors" of uric acid RDEA594 increases urinary excretion of uric acid back to normal levels Allopurinol and febuxosta
Slide 7: Dual mechanisms of xanthine oxidase and URAT1 inhibition
RDEA594 Probenecid Benzbromarone* 7 *Benzbromarone is a URAT1 inhibitor approved outside of the US and later withdrawn due to liver toxicity. Perez-Ruiz F, Arthritis Rheum 2002;47:356-360; Graphic Adapted from Hare, J. M. et al. Circulation 2003;107:1951- 1953 Pegloticase URAT1 Combining dual mechan
Slide 8: URAT1 inhibitors increase urinary excretion of uric acid
>99% Reabsorption Excretion ~100% of uric acid is initially filtered through glomerular filtration URAT1 Inhibitors Increase the Urinary Excretion of Uric Acid URAT1 Enomoto; Urat1 identification in Nature May2002 D Levinson & L Sorensen; Renal Handling of Uric Acid Proximal Tubule Benzbromarone RDE
Slide 9: Uric acid balance in gout patients
Diet & Metabolism <400 mg/day Diet & Metabolism 600-800 mg/day Joint Tophus 10 mg/dL 6.5 mg/dL serum level Xanthine Oxidase Inhibitor RDEA594 - URAT1 Inhibitor <5 mg/dL <5 mg/dL urine urine 200 mg/day 9 600 mg/day 400 mg/day gout patient
Slide 10: RDEA594 normalizes uric acid excretion
RDEA594 normalizes uric acid (UA) excretion in gout patients with inadequate excretion Allopurinol reduces UA excretion The combination of these two agents results in substantial reductions in serum uric acid (sUA) and normalized UA excretion uric acid (sUA) and normalized UA excretion uric acid (sU
Slide 11: Allopurinol arms from febuxostat Phase 3 studies
11 Allopurinol Arms from Febuxostat Phase 3 Studies Allopurinol Arms from Febuxostat Phase 3 Studies Allopurinol Arms from Febuxostat Phase 3 Studies APEX 28-week Study FACT 52-week Study CONFIRMS 28-week Study Allopurinol Dose (no. of patients) 300/100mg QD (n=263) 300mg QD (n=242) 300/100mg QD (n=
Slide 12: Competitive landscape: adverse events of xanthine oxidase inhibitors
Competitive Landscape - No Significant Difference in Adverse Events Between Xanthine Oxidase Inhibitors1 Adverse Event Placebo Febuxostat 40 mg 80 mg Febuxostat 40 mg 80 mg Allopurinol N= 134 757 1279 1277 Liver Function Abnormalities 0.7% 6.6% 4.6% 4.2% Nausea 0.7% 1.1% 1.3% 0.8% Arthralgia 0% 1.1%
Slide 13: Diagnosed gout patient segments
13 Diagnosed Gout 5 - 8 M ~90% ~50% ~50% Allopurinol Treated 2.5 M Responders (sUA<6mg/dL) 1.25 M Severe Chronic Gout 0.1 - 0.3M Allopurinol Inadequate- Responders 1.25 M ~10-20% Small % Allopurinol Intolerant Gout Pts on urate lowering therapy 2.6 M Small % Education (DTC) Improved Compliance
Slide 14: Half of treated patients still having flares
Physicians believe that approximately half of the 2.6M patients receiving treatment are still having flares* This is consistent with less than half of patients reaching target sUA on allopurinol sUA of inadequate-responders on allopurinol:* 14 14 Proportion of Subjects (%) Abstract 758: MA Becker, e
Slide 15: Combination therapy rationale for chronic therapy and treatment initiation
Chronic therapy: The combination of RDEA594 (URAT1 inhibitor) and xanthine oxidase inhibitors may produce greater reductions in sUA than either mechanism alone, with many more patients reaching levels below 6 mg/dL, and even below 5 mg/dL Reduction of sUA from 6-7mg/dL to less than 6 mg/dL reduces t
Slide 16: Summary of combination and monotherapy studies
16 Study 201 Phase 2a combination with allopurinol Combination with RDEA594 400 mg produced 100% response for sUA < 6 mg/dL Lower rate of abnormal laboratory values on RDEA594 than control Study 110 Phase 1b PK/PD combination with allopurinol Combination with RDEA594 600 mg produced 100% response fo
Slide 17: Study 111 Phase 1b febuxostat combination design
Population: 21 gout patients with hyperuricemia (sUA ^ 8 mg/dL) febuxostat 40 mg panel: 12 patients with median sUA of 9.2 mg/dL febuxostat 80 mg panel: 9 patients with median sUA of 10.4 mg/dL Objective: Plasma PK and urinary excretion of RDEA594 in combination with febuxostat; PK of colchicine alo
Slide 18: Mean sUA and percent change in sUA
RDEA594 Study 111 - Mean sUA and Percent Change in sUA febuxostat 40 mg febuxostat 80 mg All 600 mg combination values are at least p<0.05 versus 400 mg combination All combination values are p<0.001 versus to febuxostat alone 18 All combination values are p<0.001 compared to febuxostat alone All 60
Slide 19: * P<0.05, **P<0.01,***P<0.001 versus FBX mg alone # P<0.05, ## P<0.01,### P<0.001 versus FBX
* P<0.05, **P<0.01,***P<0.001 versus FBX 40 mg alone # P<0.05, ## P<0.01,### P<0.001 versus FBX 80 mg alone *** ** ** * * ### ## # # # ## ### 19
Slide 20: Febuxostat combination well tolerated
Overall, the combination of RDEA594 and febuxostat was well tolerated, with no serious adverse events, no discontinuations due to adverse events, and no increase in side effects with the combination Renal safety: Grade 2 increase in serum creatinine (SCr) on colchicine alone, no Grade 2 or greater S
Slide 21: Allopurinol combination study design
7 days 7-10 days Days 1-7 Days 8-14 Days 15-21 Days 22-28 Colchicine Treatment Allopurinol 300 mg RDEA594 400 mg Allopurinol 300 mg RDEA594 600 mg Panel 1: 10 pts Panel 2: 10 pts Population: 20 gout patients with hyperuricemia (sUA ^ 8 mg/dL) allopurinol 300 mg + RDEA594 400 mg: 10 patients, median
Slide 22: Additive urate lowering with allopurinol
Urate lowering effect of RDEA594 and allopurinol were additive when combined in this study, resulting in up to 70% reduction in sUA with patients achieving mean sUA < 3 mg/dL No clinically relevant changes in allopurinol or RDEA594 plasma levels were noted; however, there was an expected 25-35% redu
Slide 23: 100% response with combination doses
100% response with both dose combinations (p< 0.001 compared to allopurinol) RDEA594 400 mg was equivalent to allopurinol 300 mg, while RDEA594 600 mg was significantly superior (p < 0.05) *P<0.05, ** P<0.01 *** P<0.001 versus allopurinol alone ** *** *** *** * 23
Slide 24: Allopurinol combination safety and CK findings
The combination of RDEA594 and allopurinol was well tolerated, with no serious adverse events, and no discontinuations due to adverse events considered possibly related to RDEA594 or the combination No clinically relevant changes in SCr or ALT were observed Two patients receiving RDEA594 + colchicin
Slide 25: Grade 3-4 CK elevations with colchicine
Patients with Grade 3-4 CK Patients with Grade 3-4 CK Patients with Grade 3-4 CK N RDEA594 RDEA594 + Colchicine Colchicine Studies of RDEA594 Alone* 430 0% - - Study 202 123 - 2% 4% Clinically significant CK elevations have not been observed with RDEA594 alone In a large randomized, monotherapy, pla
Slide 26: Conclusions from studies
Conclusions from Studies 110 & 111 sUA reduction observed with combination therapy is far greater than what can be achieved with xanthine oxidase inhibitors alone, including the highest approved dose of febuxostat 100% response rate (sUA < 6 mg/dL) achieved with either RDEA594 + allopurinol or RDEA5
Slide 27: Phase 2b monotherapy study design
21 days 2 weeks 4 weeks 2 weeks Population: gout patients with hyperuricemia (serum uric acid ^8 mg/dL) total of 123 patients in 4 treatment arms Duration: 8 wks: 2-wk run-in, 4-wk treatment, 2-wk follow-up: dose was titrated up weekly Endpoints: Proportion of subjects with sUA level < 6.0 mg/dL at
Slide 28: Phase 2b response rates for urate reduction
Study 202 - Phase 2b Monotherapy Study Response Rates for Urate Reduction 28 ITT population n= 27 31 33 32 P=0.0001 P<0.0001 Plasma urate assay using direct LC-MS method of analysis.
Slide 29: Response rates by baseline urate levels
Study 202 - Response Rates for Plasma Urate Reduction by Baseline Urate Levels Baseline sUA 29 ITT population n= 27 31 33 32 Plasma urate assay for response using direct lc-MS method of analysis.
Slide 30: Baseline creatinine clearance by dose
30 *Creatinine clearance calculated from 24-hr urine clearance Plasma urate assay for response using indirect UV method of analysis. 200 mg 400 mg 600 mg Placebo N= 16 7 1 16 9 1 16 10 3 13 10 6 Baseline CrCL in mL/min:*
Slide 31: Phase 2b adverse events
31 *Adverse events reported by at least 2 subjects that were considered at least possibly related to treatment No Serious Adverse Events Two discontinuations due to adverse events, both on 400 mg dose: one patient with vertigo, and one patient with elevated SCr that returned to normal range while re
Slide 32: Phase 2b combination study with allopurinol ongoing
Initial dose-selection phase completed: RDEA594 200 mg, 400 mg, 600 mg to be evaluated 72 patients per dose level, including 48 patients randomized to RDEA594 and 24 patients randomized to placebo and treated for 28 days; expect at least half of patients to go into extension phase Patients must be o
Slide 33: Cancer
CANCER 33
Slide 34: MEK program licensed to Bayer HealthCare
MEK program licensed to Bayer HealthCare on April 28, 2009 $35 million upfront license fee Payments could total $407 million, excluding royalties Low double-digit royalties on worldwide sales Ardea responsible for completing two dose-finding studies MTD reached in both studies 34
Slide 35: The Age of Targeted Cancer Treatments
The Age of Targeted Cancer Treatments Nexavar MEK Ras Raf c-Myc Herceptin, Erbitux Proliferation Angiogenesis Differentiation Apoptosis cPLA2 PDE4 MNK1/2 Elk-1 MAPKAPK1/3 ARRY-142886 (Ph 2) ARRY-162 (Ph 1) XL518 (Ph 1) RDEA119 (Ph 1/2) RTK Bcl-2 Mcl-1 c-Jun Tarceva GF ERK2 ERK2 35
Slide 36: RDEA119 is a potent, highly specific MEK inhibitor
RDEA119 is Potent, Highly Specific MEK Inhibitor MEK1/2 Enzyme IC50 17-50 nM Cellular pERK EC50 2.5-8.7 nM* >100-fold selectivity in kinase panel of 205 enzymes at 10 µM** *Cell lines: Colo205, A375, A431, HT-29 ** In-house data 1 6 11 16 21 26 31 0 20 40 60 80 100 1 6 11 16 21 26 31 MEK1 & MEK2 MEK
Slide 37: Summary financials and shares outstanding
22.9 million common shares outstanding Multiple partnering opportunities Summary Statement of Operations (In thousands, except per share data) Six Months Ended June 30, 2010 Revenue Operating expenses Other expense $ 6,795 29,381 (284) NET LOSS $(22,870) NET LOSS PER SHARE $(1.11) Condensed Balance